Maternal age is one of the strongest and most well-established risk factors for chromosomal abnormalities in the developing fetus, particularly trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). The risk arises primarily from the phenomenon of non-disjunction during meiosis I in oocytes, which are arrested in prophase I from fetal life and do not complete meiosis until ovulation decades later. As oocytes age, the spindle apparatus that separates chromosomes becomes less reliable, leading to an increasing probability that a chromosome pair fails to separate correctly and produces an egg with an extra chromosome (trisomy) or a missing chromosome (monosomy). For trisomy 21, the risk at maternal age 20 is approximately 1 in 1,500, rising to 1 in 900 at age 30, 1 in 350 at age 35, 1 in 150 at age 38, 1 in 100 at age 40, and 1 in 30 at age 45. Combined first-trimester screening, now the standard of care in many countries, integrates the background age-related risk with sonographic markers (nuchal translucency thickness) and serum biochemistry (free beta-hCG and pregnancy-associated plasma protein A, PAPP-A) to generate an individualised risk estimate that is far more accurate than age alone. The UK NHS offers non-invasive prenatal testing (NIPT) to all women identified as high risk after combined first-trimester screening, while many countries now offer NIPT as primary screening. Definitive diagnosis requires invasive testing — chorionic villus sampling (CVS) or amniocentesis — which provides a fetal karyotype.
Background age-related trisomy 21 risk at age A = approximately 1 / (10^(0.286 × A - 7.1)); Combined screening risk = age-related background risk × likelihood ratio from NT + biochemistry
- 1Establish the woman's age at the expected date of delivery (EDD) — this is the relevant age for risk calculation, not age at booking.
- 2Determine the background age-related risk for trisomy 21 using published maternal age tables or the simplified formula.
- 3At 11+0 to 13+6 weeks gestation, perform first-trimester combined screening: measure nuchal translucency (NT) thickness on ultrasound; obtain serum free beta-hCG and PAPP-A levels.
- 4Convert NT, free beta-hCG, and PAPP-A to MoM (multiples of the median) values adjusted for gestational age and maternal characteristics.
- 5Use validated software (FMF algorithm or equivalent) to combine the age-related background risk with the likelihood ratios from NT and biochemistry to produce a final adjusted trisomy 21 risk.
- 6Classify as: High risk (≥1 in 150 in UK; ≥1 in 270 in US) — offer NIPT or invasive testing; Intermediate risk (1:151–1:1000 in some protocols) — offer NIPT; Low risk (<1:1000) — no further testing unless desired.
- 7If high risk: offer chorionic villus sampling (CVS) at 11–14 weeks or amniocentesis at 15+ weeks for definitive karyotype or microarray.
This is background risk only; first-trimester combined screening provides a far more accurate, individualised risk estimate
At age 23, the age-related risk of trisomy 21 is low at approximately 1:1,400. Combined screening may modify this significantly in either direction based on NT measurement and biochemistry.
Background risk for age 38 is 1:150; normal NT and biochemistry shift the risk slightly downward but remain high risk
Despite a relatively reassuring NT and normal biochemistry, the high background age-related risk results in an adjusted risk above the 1:150 threshold. NIPT or definitive invasive testing should be offered.
Elevated NT + low PAPP-A + high free beta-hCG is the classic biochemical pattern for trisomy 21
Increased NT (>3.5 mm) with low PAPP-A and elevated free beta-hCG dramatically increases the adjusted risk irrespective of maternal age. At 32 years, the background risk is moderate but the combined result is high. CVS or amniocentesis recommended.
NIPT sensitivity for trisomy 21 is >99% but false positives occur (approximately 0.1%); confirmatory karyotype is standard practice
At 45 years, the background risk is already very high. A positive NIPT result has a very high positive predictive value in this population. Amniocentesis is recommended to confirm the diagnosis, as management decisions (including possible termination) require a definitive result.
First-trimester risk counselling to help women understand their individual chromosomal risk and make informed decisions about screening.
Combined first-trimester screening programmes to identify high-risk pregnancies for NIPT or invasive testing.
Pre-conception counselling for women over 35 years planning pregnancy.
Recurrence risk counselling after a previous chromosomally abnormal pregnancy.
Epidemiological modelling of the impact of maternal age trends on the population prevalence of chromosomal conditions.
Previous trisomy 21 pregnancy
A woman who has had a previous pregnancy with trisomy 21 has an approximately 1% increased recurrence risk above her age-related background risk (unless the prior trisomy was due to an unbalanced Robertsonian translocation, in which case recurrence risk is much higher and parental karyotyping is essential).
Donor egg pregnancies
In pregnancies conceived with donor eggs, the chromosomal risk is primarily determined by the donor's age at oocyte retrieval, not the recipient's (carrying) age. First-trimester biochemistry markers (PAPP-A, free beta-hCG) may be abnormal due to the lack of genetic-uterine concordance, so NT measurement and NIPT are preferred over combined biochemistry-based screening in donor egg pregnancies.
Robertsonian translocations
Approximately 5% of trisomy 21 cases are caused by a Robertsonian translocation (usually 14;21 or 21;21) rather than free trisomy. These do not show the same maternal age association. Parental karyotyping is indicated. Recurrence risk depends on which parent carries the translocation and the chromosome involved; it can be as high as 100% for maternal 21;21 translocation.
Low PAPP-A in isolation
A low PAPP-A alone (below 0.4 MoM) in the first trimester, even with a low-risk combined screening result, is associated with increased risks of placental dysfunction, pre-eclampsia, fetal growth restriction, and stillbirth later in pregnancy. Such women warrant additional surveillance including growth scans and uterine artery Dopplers.
| Maternal Age (years) | Risk at Term (approximate) | Risk at Birth (approximate) |
|---|---|---|
| 20 | 1 in 1,500 | 1 in 1,900 |
| 25 | 1 in 1,350 | 1 in 1,600 |
| 30 | 1 in 900 | 1 in 1,000 |
| 35 | 1 in 350 | 1 in 400 |
| 38 | 1 in 150 | 1 in 180 |
| 40 | 1 in 100 | 1 in 110 |
| 42 | 1 in 60 | 1 in 70 |
| 45 | 1 in 30 | 1 in 35 |
| 48 | 1 in 15 | 1 in 18 |
Why does chromosomal risk increase with maternal age?
Female oocytes are formed during fetal development and remain arrested in meiosis I until ovulation — potentially for 40+ years. During this prolonged arrest, the spindle checkpoint mechanism that ensures accurate chromosome segregation becomes less reliable with age, increasing the probability of non-disjunction (failure to separate chromosome pairs correctly) and resulting in eggs with 24 instead of 23 chromosomes.
Does paternal age also affect chromosomal risk?
The maternal age effect is far more significant than paternal age for chromosomal trisomies, because most trisomies arise from meiotic errors in the oocyte. Advanced paternal age (>40 years) is associated with an increased risk of new (de novo) single-gene mutations causing conditions such as achondroplasia, Apert syndrome, and Noonan syndrome, but not primarily with chromosomal trisomies.
What is the difference between NIPT and combined first-trimester screening?
Combined first-trimester screening uses maternal age, NT ultrasound measurement, and serum biochemistry (PAPP-A and free beta-hCG) to generate a risk estimate; it is a screening test, not diagnostic. NIPT (non-invasive prenatal testing, also called cell-free DNA testing) analyses fragments of fetal DNA in maternal blood with very high sensitivity (>99%) and specificity for the common trisomies, making it a superior screening test. Neither is diagnostic — a definitive diagnosis requires CVS or amniocentesis.
What chromosomal conditions does maternal age screening detect?
First-trimester combined screening and NIPT are primarily designed to detect trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Extended NIPT panels also screen for sex chromosome aneuploidies (Turner syndrome XO, Klinefelter syndrome XXY, Triple X, XYY) and some panels include detection of larger chromosomal deletions (microdeletions). None of these tests detect all birth defects.
What is the nuchal translucency and what does it measure?
The nuchal translucency (NT) is the fluid-filled space at the back of the fetal neck, measured by ultrasound at 11–13+6 weeks. A thickened NT (>95th percentile for crown-rump length, approximately 3.5 mm) is associated with chromosomal abnormalities (particularly trisomy 21), structural cardiac defects, and a range of other conditions. A normal NT does not exclude all abnormalities.
Is amniocentesis or CVS safer?
Modern data from experienced operators show the procedure-related risk of miscarriage for both CVS (at 11–14 weeks) and amniocentesis (at 15+ weeks) is approximately 0.1–0.5% per procedure, somewhat lower than historical estimates. CVS provides results 4 weeks earlier than amniocentesis, which is clinically significant for decision-making. CVS carries a small risk of confined placental mosaicism complicating interpretation.
Can chromosomal risk be reduced by IVF?
IVF with preimplantation genetic testing for aneuploidy (PGT-A) screens embryos before transfer and selects euploid embryos, reducing the live birth risk of trisomy. However, PGT-A does not eliminate the risk entirely (mosaicism and false-negative results occur) and is primarily used in IVF patients with recurrent implantation failure or recurrent miscarriage, not as a routine risk-reduction strategy for older women conceiving naturally.
What if a woman declines all prenatal screening?
Prenatal screening is entirely voluntary. Women who decline should be counselled non-directively about the options available and the implications of declining. They should be offered a full structural ultrasound at the anomaly scan (20 weeks), where some chromosomal conditions and cardiac defects may be detected on fetal anatomy assessment, though sensitivity is lower than dedicated screening.
Pro Tip
Always express risk numerically (e.g., 1 in 350) rather than as a percentage alone when counselling women, as 1 in 350 is more intuitively understood than 0.3%. Some women find it helpful to understand that 349 out of 350 pregnancies at that risk level will not be affected.
Did you know?
Down syndrome was first described clinically by John Langdon Down in 1866, but it was not until 1959 that Jerome Lejeune, a French physician-geneticist, discovered that it is caused by the presence of an extra chromosome 21 (trisomy 21). Lejeune's discovery opened the entire field of clinical cytogenetics and transformed our understanding of the chromosomal basis of human developmental differences.
References
- ›Snijders RJ et al — UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks — Lancet 1998
- ›NHS Fetal Anomaly Screening Programme (FASP) — Down's, Edward's and Patau's syndrome screening
- ›ACOG Practice Bulletin — Screening for Fetal Chromosomal Abnormalities (No. 226)
- ›Fetal Medicine Foundation — First Trimester Screening